GNTA on Nasdaq

Genenta Science S.p.A.

Genenta Science S.p.A. is a biological products company, listed on Nasdaq (GNTA).1

$0.67 up 0.01 (2.26%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 20, 2026.

Overview

-6.5MNet income, fiscal 20253

Compare with another stock.

  • TickerGNTA on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersL61
  • Incorporated inItaly4
  • Business addressOlgettina, No. 58, Milan, L6 201324
  • Filer categoryNon-accelerated filer, Emerging growth company4

See how the biggest companies compare on our leaderboards

Ultimately, we hope to broaden our platform to treat a wide variety of cancers by pursuing the following strategies:5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-29.9%Return on equity3
-$6.9MFree cash flow3

Financial statements

Operating income67893-$6.6M in 2025+43% since 2019
-$15.0M-$10.0M-$5.0M02019: -$4.6M-$4.6M20192020: -$5.6M-$5.6M2020+21%2021: -$5.7M-$5.7M2021+2%2022: -$11.0M-$11.0M2022+94%2023: -$11.7M-$11.7M2023+6%2024: -$9.8M-$9.8M2024−17%2025: -$6.6M-$6.6M2025−32%
Net income67893-$6.5M in 2025+42% since 2019
-$15.0M-$10.0M-$5.0M02019: -$4.6M-$4.6M20192020: -$5.6M-$5.6M2020+22%2021: -$5.5M-$5.5M2021−1%2022: -$8.5M-$8.5M2022+53%2023: -$11.6M-$11.6M2023+37%2024: -$8.9M-$8.9M2024−23%2025: -$6.5M-$6.5M2025−27%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Research and development2.7M EUR4.8M EUR6.5M EUR
General and administrative3.9M EUR5.0M EUR5.3M EUR
Total operating expenses6.6M EUR9.8M EUR11.7M EUR
Loss from operations-6.6M EUR-9.8M EUR-11.7M EUR
Other income11.5K EUR529.7K EUR-4.9K EUR
Finance income608.5K EUR81.1K EUR309.3K EUR
Net exchange rate gain (loss)-546.1K EUR241.0K EUR-216.9K EUR
Total other income, net73.9K EUR851.8K EUR87.5K EUR
Loss before income taxes-6.5M EUR-8.9M EUR-11.6M EUR
Net loss-6.5M EUR-8.9M EUR-11.6M EUR
Earnings Per Share, Diluted-0.33 EUR-0.49 EUR-0.64 EUR
Weighted Average Number of Shares Outstanding, Diluted19.7M shares18.3M shares18.2M shares
Total change of marketable debt securities7.2K EUR-118.8K EUR215.0K EUR
Change in foreign currency translation70.4K EUR-23.4K EUR-15.9K EUR
Total other comprehensive income (loss)77.6K EUR-142.2K EUR199.1K EUR
Comprehensive loss-6.5M EUR-9.1M EUR-11.4M EUR

Compare Genenta Science S.p.A. with another company

Corporate structure

Genenta Science S.p.A. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Genenta Science S.p.A.

  • Marco Nuzzo Filed SCHEDULE 13D/A on Genenta Science S.p.A., latest Oct 2, 2026 (2 filings since May 5, 2026)
  • Paracchi Pierluigi Filed SCHEDULE 13G/A on Genenta Science S.p.A., latest Jan 27, 2026 (5 filings since Feb 14, 2022)
  • San Raffaele Ospedale Filed SC 13G on Genenta Science S.p.A., latest Feb 25, 2022
  • Luigi Naldini Filed SC 13G on Genenta Science S.p.A., latest Feb 18, 2022
  • Genenta Science S.p.A. L6

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Genenta Science S.p.A. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment61.1K EUR3 Dec 31, 202553.4K EUR3 Dec 31, 2024+14.3%
Furniture and fixtures15.6K EUR9 Dec 31, 202413.0K EUR9 Dec 31, 2023+20.0%
Computer equipment and software87.8K EUR3 Dec 31, 202587.8K EUR3 Dec 31, 20240%
Property and equipment, before depreciation148.9K EUR3 Dec 31, 2025141.2K EUR3 Dec 31, 2024+5.4%
Accumulated depreciation126.4K EUR3 Dec 31, 202598.3K EUR3 Dec 31, 2024+28.6%
Property and equipment, net22.5K EUR3 Dec 31, 202542.9K EUR3 Dec 31, 2024−47.7%

Investments

ItemLatestA year beforeChange
Marketable securities, current22.6M EUR3 Dec 31, 20258.1M EUR3 Dec 31, 2024+180.0%

Leadership

Who has led Genenta Science S.p.A., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Paracchi Pierluigi2026–now

Chief financial officer

  1. Richard B. Slansky2026–now
Board members and other officers (6)

Former names

  • Genenta Science S.r.l.Mar 1, 2021 to May 19, 20214

Timeline

  1. Mar 18, 2026New chief executive Paracchi Pierluigi becomes CEO10

Filings

108 filings to the SEC since October 2021: 6 annual reports, 12 insider forms, 9 large holders, 81 other. The latest 20:

  1. Oct 13, 20266-K EDGAR
  2. Oct 7, 20266-K EDGAR
  3. Oct 2, 2026SCHEDULE 13D/A EDGAR
  4. Sep 11, 20266-K EDGAR
  5. Sep 2, 20266-K EDGAR
  6. Jul 31, 20266-K EDGAR
  7. Jul 14, 20266-K EDGAR
  8. Jul 1, 20266-K EDGAR
  9. Jun 26, 20266-K EDGAR
  10. Jun 24, 20266-K EDGAR
  11. Jun 17, 20266-K EDGAR
  12. Jun 16, 20266-K EDGAR
  13. May 29, 20266-K EDGAR
  14. May 19, 20266-K EDGAR
  15. May 5, 2026SCHEDULE 13D EDGAR
  16. May 5, 20264 EDGAR
  17. Apr 28, 20266-K EDGAR
  18. Apr 23, 20266-K EDGAR
  19. Apr 14, 20266-K EDGAR
  20. Apr 1, 20264 EDGAR

The 108 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Marco NuzzoSCHEDULE 13D/A, 2 filings May 5, 2026 to Oct 2, 202616
  • Paracchi PierluigiSCHEDULE 13G/A, 5 filings Feb 14, 2022 to Jan 27, 202617
  • San Raffaele OspedaleSC 13G, 1 filing Feb 25, 202218
  • Luigi NaldiniSC 13G, 1 filing Feb 18, 202219

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Eurizon Capital SGR S.p.A.360,000$662.4K0.0%No change
Allianz SE234,050$430.7K0.0%No change
SmartHarvest Portfolios, LLC43,856$80.7K0.0%−90,591
Simplicity Wealth,LLC18,590$34.2K0.0%+6,379
Ground Swell Capital, LLC14,374$26.4K0.0%New
GAMMA Investing LLC9,863$18.1K0.0%−4,425
UBS Group AG3,027$5.6K0.0%−80
Virtu Financial LLC36,913$680.0%New
Farther Finance Advisors, LLC3$60.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Genenta Science S.p.A. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGenenta Science S.p.A.1
  • CIK0001838716
  • Filer statusNon-accelerated filer an emerging growth company; a shell company5
  • Incorporated inItaly5
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressOlgettina, No. 58, Milan, L6 201321
  • Phone39-02-2643-66391
  • Shares outstanding23,432,183 shares as of Dec 31, 20255
  • AuditorDannible & McKee, LLP, Syracuse, New York PCAOB ID 528; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceMar 1, 20211
  • Filings116 in all: 6-K (51), 3 (6), 4 (6), UPLOAD (6), 20-F (5), 424B5 (5), CORRESP (5), DRS/A (4)1
    All 26 form types

    DRSLTR (3), SC 13G (3), 424B1 (2), EFFECT (2), F-1/A (2), SC 13G/A (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 20-F/A (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-1MEF (1), F-3 (1), S-8 (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (20-F) Apr 1, 2026

Securities registered for trading

ClassSymbolExchange
American depositary sharesGNTANasdaq
Ordinary shares

From the cover page of the 20-F filed Apr 1, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceGNTA quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19